

2012 ONCOLOGY MARKET RESEARCH REVIEW



PHM126A
December 2012

Various Analysts
Project Analyst

ISBN: 0-89336-282-4

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 2012 ONCOLOGY MARKET RESEARCH REVIEW	1
FOREWORD	1
CHAPTER 2 MICRORNA RESEARCH TOOLS, DIAGNOSTICS AND THERAPEUTICS: GLOBAL MARKETS (REPORT BIO115A)	3
INTRODUCTION	3
STUDY GOALS AND OBJECTIVES	3
REASONS FOR DOING THIS STUDY	3
SCOPE AND FORMAT	3
METHODOLOGY AND INFORMATION SOURCES	4
INTENDED AUDIENCE	4
ANALYST CREDENTIALS	4
RELATED REPORTS	4
BCC ONLINE SERVICES	4
DISCLAIMER	5
SUMMARY	5
<i>TABLE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	7
<i>FIGURE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, 2010-2017 (\$ MILLIONS)</i>	7
INTRODUCTION TO MICRORNA RESEARCH	7
OVERVIEW	7
MICRORNA DISCOVERY	8
MICRORNA DEFINITION	9
BIOGENESIS OF MICRORNA	9
<i>FIGURE 2 SCHEMATIC REPRESENTATION OF MICRORNA BIOGENESIS AND ITS EFFECT ON PROTEIN TRANSLATION</i>	9
FUNCTION OF MICRORNA	12
MICRORNA MARKET OVERVIEW	13
Tools for Research of MicroRNA Molecules	13
<i>TABLE 2 GLOBAL MARKET FOR REAGENTS AND TOOLS FOR DNA/RNA RESEARCH, THROUGH 2016 (\$ BILLIONS)</i>	13
MicroRNA as Biomarker and its Role in Bioprofiling and Diagnostics Products Development	14
<i>TABLE 3 MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2015 (\$ BILLIONS)</i>	14
MicroRNA as Therapeutics Target in Drug Discovery	14
IMPORTANCE OF PATENTS IN MICRORNA RESEARCH	15
<i>TABLE 4 PATENTS AND PATENT APPLICATION SEARCH IN MICRORNA RESEARCH USING SPECIFIC KEY WORDS, THROUGH 2012</i>	16
miR-34 Example	16
miR-122 Case	17
<i>TABLE 5 NUMBER OF PATENTS AND PATENT APPLICATIONS IN MICRORNA RESEARCH ACCORDING TO ASSIGNEE</i>	18
CHAPTER 3 BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS (REPORT BIO022E)	22
INTRODUCTION	22
STUDY BACKGROUND	22

TOPIC	PAGE NO.
STUDY GOAL AND OBJECTIVES	22
INTENDED AUDIENCE	23
SCOPE OF REPORT	23
METHODOLOGY AND INFORMATION SOURCES	24
ANALYST CREDENTIALS	24
RELATED BCC PUBLICATIONS	24
COMMERCIAL DRUGS	25
DEVELOPMENTAL DRUGS	25
<i>TABLE 6 FDA APPROVAL PROCESS FOR NEW DRUGS</i>	25
SUMMARY	26
<i>TABLE 7 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)</i>	26
<i>FIGURE 3 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)</i>	27
OVERVIEW	28
BRIEF HISTORY OF PLANT-DERIVED MEDICINES	29
<i>TABLE 8 KEY DATES IN BOTANICAL MEDICINE</i>	30
<i>TABLE 9 WELL KNOWN PLANT-DERIVED DRUGS</i>	30
OPPORTUNITY LIES BEYOND WHAT'S KNOWN	30
<i>FIGURE 4 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S., 2000-2005* (%)</i>	31
KEY DRIVERS	32
KEY CHALLENGES	32
SIGNS OF INDUSTRY INVESTMENT	33
<i>TABLE 10 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT</i>	34
<i>TABLE 11 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS</i>	34
BOTANICAL DRUGS DEFINED	35
UNDERSTANDING THE REGULATORY PROCESS	36
<i>TABLE 12 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY</i>	38
THE FIRST APPROVED BOTANICAL	38
A GROWING PIPELINE	39
<i>FIGURE 5 INDS IN THE FDA BY THERAPEUTIC AREA (NO.)</i>	39
OVERALL PHARMA LANDSCAPE	40
<i>TABLE 13 TOP PHARMA COMPANIES BY REVENUE, 2007 (\$ BILLIONS)</i>	42
MAJOR CLASSES OF PLANT DRUGS	42
Terpenes and Steroids	42
Terpenes	42
Steroids	43
Alkaloids and Glycosides	43
Alkaloids	43
Ergot Alkaloids	44
Morphine Alkaloids	44
Vinca Alkaloids	44
Glycosides	44
Cardiac Glycosides	44
Anthraglycosides	45
Phenols	45
E. Cava Algae	45

TOPIC	PAGE NO.
Flavonoids	45
Resveratrol	45
Coumarin	45
Catechins	46
Proanthocyanidins	46
INTELLECTUAL PROPERTY	46
PRODUCTION	47
MOVING PRODUCTION FORWARD	48
ARTEMISININ: A CASE STUDY	49
SUPPLY AND LEGAL ISSUES	50
<i>TABLE 14 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS</i>	50
DRUG DEVELOPMENT AND MANUFACTURE	51
<i>TABLE 15 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES</i>	52
CHAPTER 4 GLOBAL MARKETS FOR STEM CELLS (REPORT BIO035D)	54
INTRODUCTION	54
STUDY GOALS AND OBJECTIVES	54
REASONS FOR DOING THE STUDY	54
SCOPE OF REPORT	54
MARKET ANALYSES AND FORECASTS	54
METHODOLOGY	55
INTENDED AUDIENCE	55
INFORMATION SOURCES	55
ANALYST CREDENTIALS	55
RELATED REPORTS	55
SUMMARY	55
DEFINITIONS	55
APPLICATIONS	56
RESEARCH AND COMMERCIALIZATION	56
FUNDING	56
MARKET	57
<i>TABLE 16 GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2016 (\$ MILLIONS)</i>	57
<i>FIGURE 6 GLOBAL STEM CELL MARKET AND FORECASTS, 2010-2016 (\$ MILLIONS)</i>	57
OVERVIEW	58
CELLS	58
STEM CELLS	59
<i>FIGURE 7 EARLY DEVELOPMENT OF EMBRYO</i>	59
INDUCED PLURIPOTENT STEM CELLS	61
HPSCS	61
THE CANCER PROBLEM	62
CANCER STEM CELLS-A BROADER TOPIC	63
STEM CELL RESEARCH	65
HISTORY	65
EMBRYONIC STEM CELLS	66
Growth and Identification of ESCs	66
Stimulating ESCs to Differentiate	67
ADULT STEM CELLS	67

TOPIC	PAGE NO.
Mesenchymal Stem Cells (MSCs)	67
Haematopoietic Stem Cells (HSCs)	68
Neural Stem Cell (NSC)	68
Endothelial Progenitor Cell (EPC)	68
Epithelial Stem Cell (ESC)	68
Very Small Embryonic-Like Cell (VSEL)	68
CORD BLOOD STEM CELLS	68
INDUCED PLURIPOTENT STEM CELLS (IPSCS)	69
Nuclear Reprogramming	69
CELL-BASED THERAPEUTICS	70
EMBRYONIC-DERIVED STEM CELLS	70
ADULT/PROGENITOR-DERIVED STEM CELLS	70
ENGINEERED SCS FOR TRANSPLANTATION	71
THERAPEUTIC STEM CELL BANKING	71
STEM CELL-BASED BIOMEDICAL RESEARCH	72
CHAPTER 5 BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES: GLOBAL MARKETS (REPORT HLC106A)	74
INTRODUCTION	74
STUDY GOALS AND OBJECTIVES	74
REASONS FOR DOING THE STUDY	74
SCOPE AND FORMAT	75
INTENDED AUDIENCE	75
METHODOLOGY	75
RELATED BCC STUDIES	76
ANALYST CREDENTIALS	76
SUMMARY	76
TABLE 17 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)	78
FIGURE 8 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010-2016 (\$ MILLIONS)	78
OVERVIEW	78
BREAST CANCER DIAGNOSTICS AND TRENDS	78
BREAST CANCER	79
Early Breast Cancer Detection	79
TABLE 18 POSSIBLE SIGNS OF BREAST CANCER	80
Imaging Tests	80
MAMMOGRAPHY	80
DIAGNOSTIC MAMMOGRAMS	80
TABLE 19 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER	81
Digital Mammograms	81
Usefulness of Mammography	81
MAGNETIC RESONANCE IMAGING OF THE BREAST	82
BREAST ULTRASOUND	82
DUCTAL LAVAGE AND NIPPLE ASPIRATION	82
BIOPSY	83
Fine Needle Aspiration Biopsy	83
Core Needle Biopsy	83

TOPIC	PAGE NO.
Vacuum-Assisted Biopsies	83
Surgical (Open) Biopsy	84
LYMPH NODE DISSECTION AND SENTINEL LYMPH NODE BIOPSY	84
Laboratory Examination	84
TYPES OF BREAST CANCER	84
<i>TABLE 20 BREAST CANCER GRADES</i>	85
DUCTAL CARCINOMA <i>IN SITU</i>	85
ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR STATUS	85
HER2/NEU STATUS	86
<i>TABLE 21 BIOPSY OR SURGERY SAMPLE TESTING</i>	86
GENE EXPRESSION PROFILING	86
<i>TABLE 22 TESTS USED TO EVALUATE DIFFERENT GENE SETS</i>	87
Test Usefulness	87
Imaging Tests to Determine if Breast Cancer Has Spread	87
<i>TABLE 23 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD</i>	88
THE FUTURE OF BREAST CANCER DETECTION	88
DIAGNOSTIC TESTS AND THEIR VALUE IN BREAST CANCER TESTING	88
<i>TABLE 24 HER2 TESTING AND VARIATIONS</i>	89
NEED FOR BREAST CANCER SCREENING	92
OVERDIAGNOSIS	93
Diagnosis and Treatment Regimen	93
GUIDELINES FOR BREAST CANCER DETECTION	94
<i>TABLE 25 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN</i>	95
Breast Cancer Screening Recommendations	95
USPSTF BREAST CANCER SCREENING GUIDELINES	96
<i>TABLE 26 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF</i>	96
BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS	97
BIOMARKERS AND CANCER	97
BIOMARKERS AND BREAST CANCER	98
<i>TABLE 27 BREAST CANCER PROGNOSTIC FACTORS</i>	98
<i>TABLE 28 BREAST CANCER PREDICTIVE FACTORS</i>	99
<i>TABLE 29 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (%)</i>	99
<i>TABLE 30 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%)</i>	100
HER2	100
COMPANION DIAGNOSTICS	100
TARGETED THERAPIES	100
PREDICTIVE DIAGNOSTICS	101
<i>TABLE 31 PREDICTIVE DIAGNOSTIC FEATURES</i>	101
PREDICTIVE SAFETY BIOMARKERS	101
Commercialized Biomarker Tests	102
<i>TABLE 32 CURRENT BIOMARKER TECHNOLOGIES</i>	102
<i>TABLE 33 BIOMARKER USES</i>	104
BIOMARKERS AND DRUG THERAPY	104
INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS	104
OBSTACLES TO BIOMARKER DEVELOPMENT	105
<i>TABLE 34 MAJOR ISSUES AND CHALLENGES</i>	105

TOPIC	PAGE NO.
BIOMARKER TYPES	105
Predictive Biomarkers	105
Tumor Interstitial Fluid Biomarkers	106
Pharmacogenomic Biomarkers in Drug Labels	106
BENEFITS OF PHARMACOGENOMICS	107
<i>TABLE 35 PHARMACOGENOMICS TESTS IN USE</i>	107
BARRIERS TO PHARMACOGENOMICS PROGRESS	107
Biomarkers in Drug Labels	108
CLASSIFICATION OF BIOMARKERS	108
<i>TABLE 36 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE</i>	108
<i>TABLE 37 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE</i>	109
<i>TABLE 38 CLINICALLY RELEVANT BIOMARKERS</i>	110
CHAPTER 6 LIVER DISEASE TREATMENTS: THE GLOBAL MARKET (REPORT PHM057B)	112
INTRODUCTION	112
STUDY OBJECTIVES	112
REASONS FOR DOING THIS STUDY	112
INTENDED AUDIENCE	112
SCOPE OF THE STUDY	112
METHODOLOGY	113
INFORMATION SOURCES	113
ABOUT THE AUTHOR	113
RELATED BCC RESEARCH REPORTS	113
EXECUTIVE SUMMARY	114
<i>TABLE 39 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	115
<i>FIGURE 9 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)</i>	115
OVERVIEW	116
DEFINITIONS	116
LIVER	116
FUNCTIONS OF LIVER	117
Production of Bile	117
Storage of Fats, Carbohydrates, Proteins, Vitamins and Minerals	117
Regulation of Necessary Substances in the Blood	117
Synthesis of Coagulating Proteins	118
Removal of Harmful Substances	118
Other Functions	118
COMMON SYMPTOMS OF LIVER DISEASE	118
FATIGUE	119
JAUNDICE	119
SWOLLEN ABDOMEN	119
EFFECTS OF HORMONAL IMBALANCE	119
STOOL ABNORMALITIES	119
POLYDYSPIA AND POLYURIA	119
HEPATIC ENCEPHALOPATHY	120
SEXUAL DYSFUNCTION	120
NON-SPECIFIC SYMPTOMS OF LIVER DISEASE	120

TOPIC	PAGE NO.
LIVER DISEASE	120
TABLE 40 CLASSIFICATION OF LIVER DISEASE	121
MARKET BY DISEASE TYPE	121
TABLE 41 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, THROUGH 2016 (\$ MILLIONS)	122
FIGURE 10 GLOBAL MARKET FOR DRUG USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2009-2016 (\$ MILLIONS)	122
HEPATITIS	123
TABLE 42 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, THROUGH 2016 (\$ MILLIONS)	124
FIGURE 11 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, 2009-2016 (\$ MILLIONS)	124
Global Share	125
TABLE 43 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)	125
FIGURE 12 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)	125
LIVER TUMORS	125
TABLE 44 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, THROUGH 2016 (\$ MILLIONS)	126
FIGURE 13 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2009-2016 (\$ MILLIONS)	126
Global Share	127
TABLE 45 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)	127
FIGURE 14 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)	127
AUTOIMMUNE DISEASES	128
TABLE 46 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	129
FIGURE 15 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	129
Global Share	130
TABLE 47 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)	130
FIGURE 16 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)	130
ALCOHOL-INDUCED LIVER DISEASE	130
TABLE 48 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	131
FIGURE 17 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	131
Global Share	132
TABLE 49 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)	132
FIGURE 18 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)	132
CHRONIC LIVER DISEASE	133
TABLE 50 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	134
FIGURE 19 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	134
Global Share	135
TABLE 51 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)	135

TOPIC	PAGE NO.
<i>FIGURE 20 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)</i>	135
<i>NON-ALCOHOLIC FATTY LIVER DISEASE</i>	135
<i>TABLE 52 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	136
<i>FIGURE 21 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2009-2016 (\$ MILLIONS)</i>	136
<i>Global Share</i>	137
<i>TABLE 53 GLOBAL SHARE FOR DRUGS USED TO TREAT NON ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)</i>	137
<i>FIGURE 22 GLOBAL SHARE FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)</i>	137
<i>MARKET SHARE BY DISEASE TYPE</i>	138
<i>TABLE 54 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)</i>	138
<i>FIGURE 23 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)</i>	138

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	7
TABLE 2 GLOBAL MARKET FOR REAGENTS AND TOOLS FOR DNA/RNA RESEARCH, THROUGH 2016 (\$ BILLIONS)	13
TABLE 3 MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2015 (\$ BILLIONS)	14
TABLE 4 PATENTS AND PATENT APPLICATION SEARCH IN MICRORNA RESEARCH USING SPECIFIC KEY WORDS, THROUGH 2012	16
TABLE 5 NUMBER OF PATENTS AND PATENT APPLICATIONS IN MICRORNA RESEARCH ACCORDING TO ASSIGNEE	18
TABLE 6 FDA APPROVAL PROCESS FOR NEW DRUGS	25
TABLE 7 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)	26
TABLE 8 KEY DATES IN BOTANICAL MEDICINE	30
TABLE 9 WELL KNOWN PLANT-DERIVED DRUGS	30
TABLE 10 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT	34
TABLE 11 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS	34
TABLE 12 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY	38
TABLE 13 TOP PHARMA COMPANIES BY REVENUE, 2007 (\$ BILLIONS)	42
TABLE 14 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS	50
TABLE 15 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES	52
TABLE 16 GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2016 (\$ MILLIONS)	57
TABLE 17 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)	78
TABLE 18 POSSIBLE SIGNS OF BREAST CANCER	80
TABLE 19 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER	81
TABLE 20 BREAST CANCER GRADES	85
TABLE 21 BIOPSY OR SURGERY SAMPLE TESTING	86
TABLE 22 TESTS USED TO EVALUATE DIFFERENT GENE SETS	87
TABLE 23 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD	88
TABLE 24 HER2 TESTING AND VARIATIONS	89
TABLE 25 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN	95
TABLE 26 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF	96
TABLE 27 BREAST CANCER PROGNOSTIC FACTORS	98
TABLE 28 BREAST CANCER PREDICTIVE FACTORS	99
TABLE 29 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (%)	99
TABLE 30 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%)	100
TABLE 31 PREDICTIVE DIAGNOSTIC FEATURES	101
TABLE 32 CURRENT BIOMARKER TECHNOLOGIES	102
TABLE 33 BIOMARKER USES	104
TABLE 34 MAJOR ISSUES AND CHALLENGES	105
TABLE 35 PHARMACOGENOMICS TESTS IN USE	107
TABLE 36 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE	108
TABLE 37 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE	109
TABLE 38 CLINICALLY RELEVANT BIOMARKERS	110
TABLE 39 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	115

TABLE HEADING	PAGE NO.
TABLE 40 CLASSIFICATION OF LIVER DISEASE	121
TABLE 41 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, THROUGH 2016 (\$ MILLIONS)	122
TABLE 42 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, THROUGH 2016 (\$ MILLIONS)	124
TABLE 43 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)	125
TABLE 44 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, THROUGH 2016 (\$ MILLIONS)	126
TABLE 45 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)	127
TABLE 46 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	129
TABLE 47 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)	130
TABLE 48 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	131
TABLE 49 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)	132
TABLE 50 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, THROUGH 2016 (\$ MILLIONS)	134
TABLE 51 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)	135
TABLE 52 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2016 (\$ MILLIONS)	136
TABLE 53 GLOBAL SHARE FOR DRUGS USED TO TREAT NON ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)	137
TABLE 54 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)	138

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
FIGURE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, 2010-2017 (\$ MILLIONS)	7
FIGURE 2 SCHEMATIC REPRESENTATION OF MICRORNA BIOGENESIS AND ITS EFFECT ON PROTEIN TRANSLATION	9
FIGURE 3 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)	27
FIGURE 4 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S., 2000-2005* (%)	31
FIGURE 5 INDS IN THE FDA BY THERAPEUTIC AREA (NO.)	39
FIGURE 6 GLOBAL STEM CELL MARKET AND FORECASTS, 2010-2016 (\$ MILLIONS)	57
FIGURE 7 EARLY DEVELOPMENT OF EMBRYO	59
FIGURE 8 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010-2016 (\$ MILLIONS)	78
FIGURE 9 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	115
FIGURE 10 GLOBAL MARKET FOR DRUG USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2009-2016 (\$ MILLIONS)	122
FIGURE 11 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, 2009-2016 (\$ MILLIONS)	124
FIGURE 12 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)	125
FIGURE 13 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2009-2016 (\$ MILLIONS)	126
FIGURE 14 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)	127
FIGURE 15 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	129
FIGURE 16 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)	130
FIGURE 17 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	131
FIGURE 18 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)	132
FIGURE 19 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2009-2016 (\$ MILLIONS)	134
FIGURE 20 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)	135
FIGURE 21 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2009-2016 (\$ MILLIONS)	136
FIGURE 22 GLOBAL SHARE FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)	137
FIGURE 23 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)	138